The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide, Journal of Hepatology, vol.45, issue.4, pp.529-567, 2006. ,
DOI : 10.1016/j.jhep.2006.05.013
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection ,
Peginterferon-??2a and Ribavirin Combination Therapy in Chronic Hepatitis C, Annals of Internal Medicine, vol.140, issue.5, pp.346-55, 2004. ,
DOI : 10.7326/0003-4819-140-5-200403020-00010
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, The Lancet, vol.358, issue.9286, pp.958-65, 2001. ,
DOI : 10.1016/S0140-6736(01)06102-5
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature, vol.18, issue.7262, pp.399-401, 2009. ,
DOI : 10.1038/nature08309
Genome-wide association of IL28B with response to pegylated interferon-?? and ribavirin therapy for chronic hepatitis C, Nature Genetics, vol.131, issue.10, pp.1105-1114, 2009. ,
DOI : 10.1038/ng.449
Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection, New England Journal of Medicine, vol.360, issue.18, pp.1839-50, 2009. ,
DOI : 10.1056/NEJMoa0807650
URL : https://hal.archives-ouvertes.fr/inserm-00385235
Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial, The Lancet, vol.376, issue.9742, pp.705-721, 2010. ,
DOI : 10.1016/S0140-6736(10)60934-8
Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection, New England Journal of Medicine, vol.360, issue.18, pp.1827-1865, 2009. ,
DOI : 10.1056/NEJMoa0806104
Telaprevir for Previously Treated Chronic HCV Infection, New England Journal of Medicine, vol.362, issue.14, pp.1292-303, 2010. ,
DOI : 10.1056/NEJMoa0908014
4 SVR WITH TELAPREVIR, PEGINTERFERON ALFA-2A AND RIBAVIRIN IN HCV PATIENTS WITH WELL-CHARACTERIZED PRIOR NULL RESPONSE, PARTIAL RESPONSE, VIRAL BREAKTHROUGH OR RELAPSE AFTER PR, Journal of Hepatology, vol.52, p.2, 2010. ,
DOI : 10.1016/S0168-8278(10)60006-2
Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of Phase 3 ADVANCE study HCV RESPOND-2 final results: high sustained virologic response among genotype 1 previous nonresponders and relapsers to peginterferon/ribavirin when retreated with boceprevir plus PegIntron (peginterferon alfa-2b)/ribavirin, Hepatology Hepatology, vol.5252, pp.427-442, 2010. ,
BOC) combined with peginterferon alfa-2b/ribavirin (P/R) for treatment-naive patients with hepatitis C virus (HCV) genotype 1: SPRINT-2 final results, Hepatology, vol.52, p.402, 2010. ,
Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naive genotype 1 HCV patients who achieved an extended rapid viral response: final results of Phase 3 ILLUMINATE study, Hepatology, vol.52, p.401, 2010. ,
Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study, Hepatology Gastroenterology, vol.138, pp.1338-1383, 2010. ,
Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and Ribavirin, Gastroenterology, vol.138, issue.7, pp.2307-2321, 2010. ,
DOI : 10.1053/j.gastro.2010.02.009
Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method, Hepatology, vol.44, issue.1, pp.22-31, 2007. ,
DOI : 10.1002/hep.21656
A Sustained Virologic Response Is Durable in Patients With Chronic Hepatitis C Treated With Peginterferon Alfa-2a and Ribavirin, Gastroenterology, vol.139, issue.5, pp.1593-601, 2010. ,
DOI : 10.1053/j.gastro.2010.07.009
IL28B polymorphism is associated with both side effects and clearance of hepatitis C during interferon-alpha therapy, J Interferon Cytokine Res, 2010. ,
Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial, Ann Intern Med, vol.150, pp.528-568, 2009. ,
Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy, Gastroenterology, vol.136, issue.5, pp.1618-1646, 2009. ,
DOI : 10.1053/j.gastro.2009.01.039
Pegylated Interferon Alfa-2b Plus Ribavirin in the Retreatment of Interferon-Ribavirin Nonresponder Patients, Gastroenterology, vol.130, issue.4, pp.1098-106, 2006. ,
DOI : 10.1053/j.gastro.2006.02.016
2011 IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-?? AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION, Journal of Hepatology, vol.52, p.468, 2010. ,
DOI : 10.1016/S0168-8278(10)61202-0